IP Library Granted Patent US 8,273,553
Granted Patent B2
US 8,273,553 · App. 12/761,554 · Granted Sep 25, 2012

Production of growth hormone in serum-free cell culture medium for mammalian cells

Assignee: Ares Trading S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,553
App. No.
12/761,554
Granted
Sep 25, 2012
Kind
B2
Abstract

The invention relates to a process for the manufacturing of a protein, such as growth hormone, in mammalian cells cultured in a serum-free medium (medium free of components derived from animal serum). The medium contains cobalt and, optionally, cadmium or cyclodextrin.

Claims (19)

1. A process for the production of growth hormone comprising the step of culturing cells of a cell line expressing growth hormone in a cell culture medium free of components derived from animal serum, the medium comprising cobalt in a concentration ranging from about 0.5 μM to about 20 μM and cadmium at a concentration of about 10 nM to about 100 nM, wherein the growth hormone is expressed under the control of a metallothionein promoter.

2. The process according to claim 1 , wherein said medium comprises cobalt at a concentration of: a) 1 μM to about 10 μM; b) 5 μM to about 15 μM; c) 7.5 μM to about 12 μM; d) 0.5 μM to about 2.5 μM; e) 0.5 μM to about 2 μM; f) 0.75 μM to about 1.5 μM; g) about 1.0 μM; h) 0.5 μM to about 12.5 μM; i) about 10 μM; or j) about 20 μM.

3. The process according to claim 1 , wherein said medium comprises cadmium at a concentration of about 20 nM to about 100 nM.

4. The process according to claim 1 , wherein said medium comprises cadmium at a concentration of about 50 nM to about 100 nM.

5. The process according to claim 1 , wherein said medium comprises cobalt at a concentration of about 1 μM and cadmium at a concentration of about 100 nM.

6. The process according to claim 1 , wherein said medium further comprises methyl-beta-cyclodextrin at a concentration of about 0.02 mM to about 0.1 mM.

7. The process according to claim 6 , wherein said medium comprises methyl-beta-cyclodextrin at a concentration of about 0.04 mM to about 0.1 mM; or about 0.07 mM to about 0.1 mM.

8. The process according to claim 1 , wherein said medium further comprises ferric ions at a concentration of 5 μM or 6 μM, zinc at a concentration ranging from 0.2 μM to 0.5 μM and copper at a concentration of 25 nM.

9. The process according to claim 8 , wherein the medium comprises zinc at a concentration of 0.2 μM or 0.5 μM.

10. The process according to claim 1 , further comprising collecting the growth hormone from the cell culture.

11. The process according to claim 1 , further comprising purifying the growth hormone.

12. The process according to claim 11 , further comprising formulating the purified growth hormone with a pharmaceutically acceptable carrier to obtain a pharmaceutical composition.

13. The process according to claim 1 , wherein the growth hormone is human growth hormone.

14. A process for the production of growth hormone comprising the step of culturing cells of a cell line expressing growth hormone in a cell culture medium free of components derived from animal serum, the medium comprising cadmium at a concentration of about 10 nM to about 100 nM, wherein the growth hormone is expressed under the control of a metallothionein promoter.

15. The process according to claim 14 , wherein said medium comprises cadmium at a concentration of about 50 nM to about 100 nM.

16. A process for the production of growth hormone comprising the step of culturing cells of a cell line expressing growth hormone in a cell culture medium free of components derived from animal serum, the medium comprising methyl-beta-cyclodextrin at a concentration of about 0.02 mM to about 0.1 mM, wherein the growth hormone is expressed under the control of a metallothionein promoter.

17. The process according to claim 16 , wherein said medium comprises methyl-beta-cyclodextrin at a concentration of: about 0.04 mM to about 0.1 mM; or about 0.07 mM to about 0.1 mM.

18. The process according to claim 1 , wherein the metallothionein promoter is the mouse MT-1 promoter.

19. The process according to claim 1 , wherein the cells are mouse C127 cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2010
From: HERNANDEZ, JOSE CASATORRES; PIERA, CARLOS MARTIN
To: ARES TRADING S.A.
Reel/Frame 024430/0800 →
Priority Claims (1)
EP 04105451 · Nov 2, 2004 · regional
Continuity (3)
Continuation In Part 11576277
Provisional Application 60624885 · Nov 4, 2004
Related Publication 20100227819A1 · Sep 9, 2010